Plakun Eric M
PLAKUN: Associate Medical Director, Director of Biopsychosocial Advocacy, Austen Riggs Center, Stockbridge, MA, and Leader, the American Psychiatric Association Psychotherapy Caucus, Arlington, VA.
J Psychiatr Pract. 2017 Mar;23(2):130-133. doi: 10.1097/PRA.0000000000000217.
There is a need for psychotherapy research to determine the effective, nonspecific or shared elements of psychotherapy regardless of therapy school. In an apparent "either/or" rather than "both/and" choice, the National Institute of Mental Health (NIMH) has committed its research resources to study of neural mechanisms and biomarkers, while greatly reducing funding for research into clinical methods, including psychotherapy. This column explores the potential effect of this decision on patient care and reviews questions raised by some about whether the underlying "big idea" behind the NIMH research approach is supported by the results of several decades of brain and genomics research. Patients are left to hope for clinically meaningful research findings concerning brain or gene mechanisms of mental disorders, as if they are just around the corner, when the actual benefit of such research likely remains decades away.
心理治疗研究需要确定心理治疗的有效、非特异性或共同要素,而不考虑治疗流派。美国国立精神卫生研究所(NIMH)显然做出了“非此即彼”而非“两者兼顾”的选择,将其研究资源投入到神经机制和生物标志物的研究中,同时大幅削减了包括心理治疗在内的临床方法研究的资金。本专栏探讨了这一决定对患者护理的潜在影响,并审视了一些人提出的问题,即NIMH研究方法背后的潜在“大理念”是否得到了数十年大脑和基因组学研究结果的支持。患者只能寄希望于获得关于精神障碍大脑或基因机制的具有临床意义的研究发现,就好像这些发现近在咫尺,而实际上此类研究的实际益处可能仍需几十年才能实现。